Solid Tumor Malignancies Clinical Trial
Official title:
Phase I Trial of ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies
The purpose of this study is to find out the highest tolerated dose of Depakote in combination with liposome encapsulated all-trans retinoic acid (ATRA-IV) in patients with advanced solid tumor malignancies.
To determine the maximum tolerated dose of Depakote in combination with liposome
encapsulated all-trans retinoic acid (ATRA-IV) in patients with advanced solid tumor
malignancies.
This will be a 2-step dose escalation study. Once the patient starts therapy at a designated
dose level, it will not be escalated for that patient. Three patients at each dose level
must complete 4 weeks of therapy before escalating to the next higher level. If none of the
patients experience dose limiting toxicity (DLT), then 3 new patients will be treated with
the next higher dose level.
;
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04668833 -
ALI Post Radiation Therapy in Patients With Lung and Esophageal Canter
|
Phase 2 | |
Recruiting |
NCT05085548 -
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
|
Phase 1 | |
Completed |
NCT01924689 -
Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
|
Phase 1 | |
Completed |
NCT00310895 -
Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies
|
Phase 1 | |
Completed |
NCT01183364 -
A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors
|
Phase 1 | |
Terminated |
NCT01290380 -
A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies
|
Phase 1 | |
Terminated |
NCT01118819 -
Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
|
Phase 1 |